Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for 2025-2034.
Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A) biologic activity (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic therapy approved for the treatment of human cancer. The drug was developed by F. Hoffmann-La Roche AG and approved by US FDA in February 2004 as first-line therapy in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer. Bevacizumab is approved for the treatment of patients with cervical, epithelial ovarian, and fallopian tube cancer in the United States and Europe.
Bevacizumab is also approved for the treatment of patients with non-small-cell lung cancer and metastatic renal cell carcinoma. Also, it is indicated for the treatment of patients with glioblastoma in the United States and use in metastatic breast cancer in Europe. Bevacizumab is approved by European Medicines Agency in 2005 and marketed under the trade name Avastin.
Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. Due to the high cost of the biologics, significant companies are focused on the development of biosimilar to fulfill the need of low-income patients as well as expand their coverage. Patent of avastin will expire in Europe in 2022, and in the U.S., the patent will expire in 2019. Thus many biosimilar of bevacizumab is in development phase and are expected to come into the market in the forecast period. Introduction to biosimilars, increase in incidence and prevalence rate of various cancer, rising demand for targeted therapy, and price cuts have boosted the growth of bevcizumab biosimilar market. However, the stringent regulatory process for the approval of bevacizumab biosimilar, intense competition, and disappointing pipeline results are the major restraining factors for the growth of the bevacizumab biosimilar market.
The Bevacizumab biosimilar market is segmented into product, application and distribution channel. Accoriding to the product segment, the market includes Abevmy, Alymsys, Avastin, Avzivi, Avzivi tnjn, Aybintio, Bambevi, Equidacent, Jobevne, Lextemy, Lytenava, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev, and others (including products approved in developing countries and pipeline products). Based on application, the global bevacizumab biosimilar market is segmented in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Non-Small Cell Lung Cancer and Colorectal Cancer segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate. Based on distribution channel the global bevacizumab biosimilar market is segmented as hospital pharmacy, online pharmacy and others. Hospital pharmacy segment is expected to grow during forecast period due to increase in number of hospital visit and hospital stays.
At regional level, the global bevacizumab biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global bevacizumanb biosimilar market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Early availability of biosimilar and emerging and huge population base countries such as China and India offers tremendous market opportunities for the bevacizumab biosimilar market.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 9.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Application, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Amgen, AryoGen Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio, TOT Biopharm, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Bevacizumab Biosimilar Market Snapshot
Chapter 4. Global Bevacizumab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Porter’s Five Forces Analysis
4.6. Impact of COVID 19 Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Major Investment, Partnerships and Collaborations in Biosimilar Industry
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Products:
5.2.1. Avastin
5.2.2. Mvasi
5.2.3. Zirabev
5.2.4. Aybintio
5.2.5. Other Clinical Trial Products
Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Applications & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Applications:
6.2.1. Colorectal cancer
6.2.2. Non-small cell lung cancer
6.2.3. Glioblastoma
6.2.4. Renal cell carcinoma
6.2.5. Cervical cancer
6.2.6. Ovarian cancer
Chapter 7. Market Segmentation 3: By End-Users Estimates & Trend Analysis
7.1. By End-Users & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By End-Users:
7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels
Chapter 8. Bevacizumab Biosimilar Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Products, 2025-2034
8.1.2. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Applications, 2025-2034
8.1.3. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by End-Users, 2025-2034
8.1.4. North America Bevacizumab Biosimilar Market Revenue (US$ Million) Estimates and Forecasts by Country, 2025-2034
8.2. Europe
8.2.1. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, 2025-2034
8.2.2. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, 2025-2034
8.2.3. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, 2025-2034
8.2.4. Europe Bevacizumab Biosimilar Market Revenue (US$ Million) by Country, 2025-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, 2025-2034
8.3.2. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, 2025-2034
8.3.3. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, 2025-2034
8.3.4. Asia Pacific Bevacizumab Biosimilar Market Revenue (US$ Million) by Country, 2025-2034
8.4. Latin America
8.4.1. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, (US$ Million) 2025-2034
8.4.2. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, (US$ Million) 2025-2034
8.4.3. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, (US$ Million) 2025-2034
8.4.4. Latin America Bevacizumab Biosimilar Market Revenue (US$ Million) by country, (US$ Million) 2025-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by Products, (US$ Million) 2025-2034
8.5.2. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by Applications, (US$ Million) 2025-2034
8.5.3. Middle East & Africa Bevacizumab Biosimilar Market Revenue (US$ Million) by End-Users, (US$ Million) 2025-2034
8.5.4. Middle East & Africa Bevacizumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2025-2034
Chapter 9. Competitive Landscape
9.1. Company Profiles
9.1.1. Amgen Inc.
9.1.2. Amneal Pharmaceuticals, Inc.
9.1.3. Betta Pharmaceuticals/Beijing Mabworks
9.1.4. Biocon
9.1.5. Biosimilar Collaborations Ireland Limited
9.1.6. Bio-Thera Solutions, Ltd.
9.1.7. Celltrion, Inc.
9.1.8. Cipla
9.1.9. Dr. Reddy’s Laboratories
9.1.10. FGK Representative Service GmbH
9.1.11. Hetero
9.1.12. Innovent Biologics
9.1.13. mAbxience Holding, S.L.
9.1.14. Outlook Therapeutics Limited
9.1.15. Pfizer Inc.
9.1.16. Reliance Life Sciences
9.1.17. Roche Registration GmbH
9.1.18. Samsung Bioepis NL B.V.
9.1.19. Sandoz Inc.
9.1.20. Shanghai Henlius Biotech
9.1.21. STADA Arzneimittel AG
9.1.22. TOT BIOPHARM
9.1.23. Zydus Cadila
9.1.24. AstraZeneca PLC
9.1.25. Samsung Bioepis Co., Ltd.
9.1.26. Organon & Co.
9.1.27. Prestige Biopharma Ltd.
9.1.28. Zhejiang Teruisi Pharmaceutical Co., Ltd.
9.1.29. Apotex Inc.
9.1.30. Tanvex BioPharma Inc.
9.1.31. Other Prominent Player
Global Bevacizumab Biosimilar Market Outlook By Product
Global Bevacizumab Biosimilar Market Outlook By Application
Global Bevacizumab Biosimilar Market Outlook By Distribution Channel
Global Bevacizumab Biosimilar Market Outlook By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
